Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

Sonoma Pharmaceuticals (NASDAQ:SNOA) priced a firm-commitment public offering expected to raise approximately $4.0 million gross.

Rhea-AI Summary

Sonoma Pharmaceuticals (NASDAQ:SNOA) priced a firm-commitment public offering expected to raise approximately $4.0 million gross. The offering includes 2,962,963 shares of common stock and 2,962,963 warrants at a purchase and exercise price of $1.35 each.

The company granted Dawson James Securities a 45-day overallotment option for up to 15% of the shares or warrants. Closing is expected on April 27, 2026. The company expects to use net proceeds for general corporate purposes, including working capital. A Form S-1 was declared effective on April 23, 2026.

Positive

• Expected gross proceeds of $4.0 million
• Net proceeds designated for general corporate purposes, including working capital

Negative

• Issuance of 2,962,963 shares and matching warrants creates immediate dilution
• Underwriter has a 45-day option to cover up to 15% overallotments, increasing potential dilution

Argus Apr 24 session

-36.67% close to close Open Argus

Details

News Market Reaction – SNOA

In the Apr 24 session, SNOA declined 36.67%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -36.7% in the session following this news. A negative reaction despite the modest ...

Analysis

The stock dropped -36.7% in the session following this news. A negative reaction despite the modest $4.0 million raise fits a pattern where positive or strategic news sometimes preceded declines, such as the -8.24% move after the CVS and Walmart burn hydrogel launch. Shares already traded 73.99% below the 52-week high and below the $3.44 200-day MA, so additional dilution pressure could have amplified selling. Elevated volume at 3.63x the 20-day average underscores sensitivity to financing terms.

Key Figures

Gross proceeds: $4.0 million Shares offered: 2,962,963 shares Warrants offered: 2,962,963 warrants +5 more

Gross proceeds

$4.0 million

Expected gross proceeds from public offering before fees and expenses

Shares offered

2,962,963 shares

Common stock offered in public offering

Warrants offered

2,962,963 warrants

Warrants issued in public offering

Offering price

$1.35 per share

Purchase price for each share of common stock in offering

Warrant exercise price

$1.35 per share

Exercise price for each warrant issued in offering

Over-allotment option

15%

Underwriter 45-day option on additional shares or warrants

Expected closing date

April 27, 2026

Target closing date for the public offering

S-1 effective date

April 23, 2026

Date Form S-1 registration statement was declared effective by SEC

Historical Context

5 past events · Latest: Mar 24

5 events

1. Mar 24

   Retail product launch

   24h Move

   -8.2%

   U.S. retail launch of HOCl burn relief hydrogel in CVS and Walmart.

2. Mar 18

   Dermatology launch

   24h Move

   +2.9%

   Launch of Aquanil AD HOCl dermatology line for sensitive skin OTC.

3. Feb 10

   Earnings results

   24h Move

   +1.4%

   Q3 2026 results showing revenue growth and improved gross margin, smaller loss.

4. Jan 28

   Board changes

   24h Move

   -1.5%

   Board refresh and new SVP for regulatory, quality and product development.

5. Nov 13

   Product recognition

   24h Move

   -3.8%

   Reliefacyn hydrogel earning National Rosacea Society Seal of Acceptance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hypochlorous acid, warrants, over-allotments, form s-1, +1 more

5 terms

hypochlorous acid medical

"a global healthcare leader in hypochlorous acid (HOCl) technology, today annou"

A mild, naturally occurring chemical formed when chlorine dissolves in water that acts as a fast-acting disinfectant and antiseptic. Think of it like a gentle, short-lived version of bleach that kills bacteria and viruses without strong fumes or persistent chemical residue. Investors watch it because demand, regulatory approvals, production capacity and safety perceptions directly affect sales in cleaning, healthcare and water-treatment markets, influencing product lines and revenue.

warrants financial

"The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants."

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

over-allotments financial

"option to purchase up to 15% of the number of shares or warrants sold in the offering solely to cover over-allotments, if any."

An over-allotment is a temporary extra batch of shares that the underwriters of a stock offering are allowed to sell beyond the original amount, with the right to buy those shares back later. Think of it as spare tickets sold to meet demand and then reclaimed if needed to keep the market orderly; it helps stabilize the stock price after an offering and can affect short-term supply and potential dilution, which matters to investors tracking price and ownership stakes.

form s-1 regulatory

"A registration statement on Form S-1 relating to the offering of the securities was filed"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

prospectus regulatory

"The offering is being made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4.0 million, before deducting fees and other expenses payable by the Company. The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants. Each share of common stock is being sold at a purchase price of $1.35 per share. The warrants have an exercise price of $1.35 per share.

In addition, Sonoma Pharmaceuticals has granted Dawson James Securities a 45-day option to purchase up to 15% of the number of shares or warrants sold in the offering solely to cover over-allotments, if any.

The offering is expected to close on April 27, 2026, subject to the satisfaction of customary closing conditions.

The Company expects to use the net proceeds from the offering for general corporate purposes, including working capital.

Dawson James Securities is acting as sole bookrunner for the offering.

A registration statement on Form S-1 relating to the offering of the securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on April 23, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the proposed transaction may be obtained, when available, on the SEC's website, www.sec.gov or by contacting Dawson James Securities. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals^™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com

SOURCE: Sonoma Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Sonoma Pharmaceuticals (SNOA) raising in the April 2026 public offering?

The offering is expected to raise approximately $4.0 million gross. According to the company, proceeds come from sale of 2,962,963 shares and 2,962,963 warrants at a purchase and exercise price of $1.35 each.

What are the terms of the warrants included in SNOA's offering?

Each warrant has an exercise price of $1.35 per share. According to the company, the offering pairs one warrant with each share sold, totaling 2,962,963 warrants issued alongside the common shares.

When will the Sonoma Pharmaceuticals (SNOA) offering close and what approvals are in place?

The offering is expected to close on April 27, 2026, subject to customary conditions. According to the company, a Form S-1 registration statement was declared effective by the SEC on April 23, 2026.

How might the SNOA offering affect existing shareholders?

Existing shareholders may experience dilution from issuance of 2,962,963 shares and warrants. According to the company, Dawson James Securities also holds a 45-day option up to 15% for over-allotments, which could increase dilution.

What will Sonoma Pharmaceuticals (SNOA) use the proceeds from the offering for?

Proceeds are expected to be used for general corporate purposes, including working capital. According to the company, net proceeds will support ongoing operations and corporate needs but no specific projects or amounts were disclosed.